AstraZeneca’s AZD9056 Shows Promise in Phase IIa Study on Moderate to Severe Crohn’s Disease

AstraZeneca’s AZD9056 Shows Promise in Phase IIa Study on Moderate to Severe Crohn’s Disease

According to a recently published study, AstraZeneca's AZD9056 - an orally-available purinergic receptor P2X7 antagonist, may be effective in symptom improvement in patients with moderate to severe Crohn's disease. The study is titled, "Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study", and is published in the journal Inflammatory Bowel Diseases.

Investigators Jean-Frédéric Colombel, MD, professor of medicine at the Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, and Séverine Vermeire, MD, PhD, from the department of gastroenterology at the Catholic University of Leuven in Belgium, and colleagues explained that the P2X7 receptor plays a major role in the conversion and production of a number of proinflammatory cytokines that are known to drive Crohn's disease.

“AZD9056 is a selective oral inhibitor of P2X7 receptor signaling identified through high throughput screening and has been previously studied in patients with rheumatoid arthritis.” wrote the research team according to a

Subscribe or to access all post and page content.